Triamcinolone or Bevacizumab for Central Retinal Vein Occlusion With Poor Vision

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

38 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-01-31

Study Completion Date

2010-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the effect of intravitreal bevacizumab with intravitreal triamcinolone for the treatment of central retinal vein occlusion (CRVO) presenting poor visual acuity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO)

NCT01178697

Central Retinal Vein Occlusion

UNKNOWN PHASE2

Intravitreal Avastin Versus Intravitreal Avastin and Triamcinolone in Central Retinal Vein Occlusion(CRVO)

NCT00370630

Retinovascular Disease

UNKNOWN PHASE2

Intravitreal Bevacizumab and Triamcinolone in Diabetic Macular Edema

NCT01342159

Diabetic Macular Edema

COMPLETED NA

Bevacizumab for Central Retinal Vein Occlusion Study

NCT00906685

Central Retinal Vein Occlusion

COMPLETED PHASE3

Combined Triple Procedure in Retinal Vein Occlusion (RVO)

NCT00805064

Retinal Vein Occlusion

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Central Retinal Vein Occlusion With 20/200 or Worse Visual Acuity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

bevacizumab

intravitreal bevacizumab or triamcinolone determined by single physician

Group Type ACTIVE_COMPARATOR

intravitreal injection

Intervention Type PROCEDURE

intravitreal bevacizumab( 1.25 mg) or triamcinolone( 4mg) injection

triamcinolone

Group Type ACTIVE_COMPARATOR

intravitreal injection

Intervention Type PROCEDURE

intravitreal bevacizumab( 1.25 mg) or triamcinolone( 4mg) injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

intravitreal injection

intravitreal bevacizumab( 1.25 mg) or triamcinolone( 4mg) injection

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* central macular thickness of more than 250 μm and baseline visual acuity of 20/200 or worse than 20/200 in patient with central retinal vein occlusion

Exclusion Criteria

* previous treatment such as intravitreal injection, subtenon injection, or laser photocoagulation since the time of onset
* Patients with a history of glaucoma, neovascular glaucoma, diabetic retinopathy, and macular disorders
* neovascularization on the disc or elsewhere or rubeosis

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No